The most severe risk is launch execution for Lifyorli: if US adoption or European reimbursement disappoints, the $1.05 billion revenue outlook could be delayed, triggering a sharp de-rating (analyst low target $50.00, -55%). Second is generic erosion of Korlym, which still generates the bulk of revenue; faster-than-expected generic entry would pressure the base business. Third is valuation compression: at EV/EBITDA 51.2x and P/CF 25.5x, the stock is vulnerable to rising interest rates or sector rotation away from high-multiple biotech. Fourth is earnings volatility: Q1 2026 produced a $31.2 million net loss, and trailing EPS of $0.03 yields a negative PEG ratio, highlighting the lumpiness of profitability. Ranked by severity: launch execution, Korlym generic erosion, valuation compression, earnings volatility.

The 12-month forecast has three scenarios: bull case (30% probability) targets $141-165, driven by strong Lifyorli uptake and timely EU reimbursement; base case (50% probability) targets $110-141, assuming steady launch progress and stable Korlym; bear case (20% probability) targets $50-80, reflecting launch disappointment or generic erosion. The most likely scenario is the base case, with a target range around the current price to the average analyst target of $141. The key assumption behind the base case is that Q3 2026 revenue grows to approximately $270-280 million and operating margins expand. The probabilities sum to 100%, and the expected value weighted by probability is approximately $118, implying modest upside from $110.16.

CORT appears fairly valued to slightly overvalued on trailing metrics but reasonably valued on forward earnings. The trailing P/E of 36.6x and EV/EBITDA of 51.2x are premium multiples, reflecting the market's expectation of continued strong growth. However, the forward P/E of 25.0x is more palatable when compared to the 31.7% revenue growth rate, implying a forward PEG of roughly 0.8. The price-to-sales ratio of 4.75x is moderate for a high-growth biopharma. Compared to its own history, the stock's 138.6% six-month rally has expanded multiples, but the Lifyorli approval justifies a re-rating. The market is pricing in successful execution of the oncology launch; any disappointment could lead to multiple compression toward the analyst low target of $50.00.

From a risk/reward perspective, CORT offers 28% upside to the average analyst target of $141.00 and 50% upside to the high target of $165.00, against a downside to the analyst low of $50.00 (55% loss) and the 52-week low of $28.66 (74% loss). The valuation is rich on trailing metrics (P/E 36.6x, EV/EBITDA 51.2x) but reasonable on forward earnings (P/E 25.0x) given 31.7% revenue growth. The biggest downside risk is Lifyorli launch failure or delay, which would undermine the dual-franchise thesis. For growth-oriented investors with a 2-3 year horizon and tolerance for volatility (max drawdown -64.4%), CORT is a good buy at current levels, but position sizing should reflect the binary launch risk. It is less suitable for conservative or income-focused investors.

CORT is best suited for a medium-to-long-term investment horizon of at least 2-3 years, given the binary nature of the Lifyorli launch and the time required for European reimbursement and pipeline maturation. The stock's beta of 0.401 suggests lower volatility than the market, but its max drawdown of -64.4% and 138.6% six-month rally indicate high idiosyncratic risk, making it unsuitable for short-term trading unless one has a high risk tolerance. The lack of a dividend (payout ratio 0%) means returns depend entirely on capital appreciation. Earnings visibility is improving but still lumpy (Q1 loss, Q2 profit), so long-term holders should be prepared for quarterly volatility. A minimum holding period of 2 years is recommended to allow the oncology franchise to scale and to ride out launch-related fluctuations.